GEOVAX LABS, INC. (OTCMKTS:GOVX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07Submission of Matters to a Vote of Security Holders.
The Company held its annual meeting of the stockholders on June
5, 2017. The Company received proxies totaling approximately
77.37% of its issued and outstanding shares of common stock
representing 45,434,125 shares of common stock, as of the record
date of April 12, 2017. The stockholders voted on the following
proposals and the results of the voting are presented below.
Election of Directors
Our stockholders approved the slate of directors consisting of
six members to hold office until the next annual meeting of
stockholders or until their successors are duly elected and
qualified. There were a total of 31,817,010 broker non-votes on
this item.
|
Nominee |
For |
Withheld |
|
Randal D. Chase |
12,550,224 |
1,066,891 |
|
David A. Dodd |
12,430,899 |
1,186,216 |
|
Dean G. Kollintzas |
12,552,320 |
1,064,795 |
|
Robert T. McNally |
12,595,319 |
1,021,796 |
|
Harriet L. Robinson |
12,565,247 |
1,051,868 |
|
John N. Spencer, Jr. |
12,561,117 |
1,055,998 |
Ratification of Independent Auditor
Our stockholders approved the ratification of Porter Keadle Moore
LLC as our independent registered public accounting firm for the
fiscal year ending December31, 2017. There were no broker
non-votes on this item.
|
For |
Against |
Abstain |
|
42,279,433 |
2,199,938 |
954,754 |
Advisory Vote on Executive Compensation
Our stockholders approved, on a non-binding advisory basis, the
compensation of our named executive officers. There were a total
of 31,817,010 broker non-votes on this item.
|
For |
Against |
Abstain |
|
11,963,268 |
1,151,877 |
501,970 |
About GEOVAX LABS, INC. (OTCMKTS:GOVX)
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company’s development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company’s clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.